Michael Gelband’s Exact Sciences EXAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-266,329
| Closed | -$27.4M | – | 1713 |
|
|
2025
Q4 | $27M | Buy |
266,329
+191,023
| +254% | +$15.3M | 0.21% | 65 |
|
|
2025
Q3 | $4.12M | Buy |
75,306
+9,605
| +15% | +$480K | 0.04% | 482 |
|
|
2025
Q2 | $3.49M | Buy |
+65,701
| New | +$3.34M | 0.03% | 534 |
|
|
2025
Q1 | – | Sell |
-195,791
| Closed | -$11M | – | 1623 |
|
|
2024
Q4 | $11M | Buy |
195,791
+135,245
| +223% | +$8.42M | 0.08% | 247 |
|
|
2024
Q3 | $4.12M | Buy |
+60,546
| New | +$3.42M | 0.03% | 490 |
|
|
2024
Q2 | – | Sell |
-203,378
| Closed | -$14M | – | 1647 |
|
|
2024
Q1 | $14M | Sell |
203,378
-16,685
| -8% | -$1.06M | 0.11% | 154 |
|
|
2023
Q4 | $16.3M | Buy |
220,063
+97,743
| +80% | +$6.41M | 0.11% | 134 |
|
|
2023
Q3 | $8.35M | Buy |
122,320
+104,842
| +600% | +$8.9M | 0.08% | 259 |
|
|
2023
Q2 | $1.64M | Buy |
17,478
+3,916
| +29% | +$305K | 0.01% | 893 |
|
|
2023
Q1 | $920K | Sell |
13,562
-44,730
| -77% | -$2.88M | 0.01% | 1167 |
|
|
2022
Q4 | $2.89M | Sell |
58,292
-12,600
| -18% | -$515K | 0.04% | 516 |
|
|
2022
Q3 | $2.3M | Buy |
+70,892
| New | +$2.92M | 0.03% | 738 |
|
|
2022
Q1 | – | Sell |
-12,639
| Closed | -$984K | – | 2322 |
|
|
2021
Q4 | $984K | Buy |
+12,639
| New | +$1.12M | 0.01% | 1083 |
|
|
2021
Q1 | – | Sell |
-4,018
| Closed | -$532K | – | 2242 |
|
|
2020
Q4 | $532K | Buy |
4,018
+2,933
| +270% | +$355K | 0.01% | 1210 |
|
|
2020
Q3 | $111K | Sell |
1,085
-27,143
| -96% | -$2.34M | ﹤0.01% | 1578 |
|
|
2020
Q2 | $2.45M | Buy |
+28,228
| New | +$2.26M | 0.06% | 350 |
|
|
2020
Q1 | – | Sell |
-2,385
| Closed | -$221K | – | 1238 |
|
|
2019
Q4 | $221K | Sell |
2,385
-515
| -18% | -$45.3K | ﹤0.01% | 1300 |
|
|
2019
Q3 | $262K | Buy |
+2,900
| New | +$330K | 0.01% | 964 |
|
|
2019
Q2 | – | Sell |
-78,819
| Closed | -$6.83M | – | 1173 |
|
|
2019
Q1 | $6.83M | Buy |
+78,819
| New | +$6.71M | 0.51% | 28 |
|
Other funds holding EXAS
Michael Gelband's EXAS Position: Q1 2026 in Review
Michael Gelband sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 266,329 shares — an estimated $27.4M sold.
Michael Gelband first reported a position in EXAS in Q1 2019 and held it in 19 quarters. The position peaked at $27M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.
- Michael Gelband reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
- Michael Gelband sold 266,329 Exact Sciences shares in Q1 2026, an estimated $27.4M.
- Michael Gelband first reported a position in Exact Sciences in Q1 2019 and held it in 19 quarters.
- Michael Gelband's Exact Sciences position peaked at $27M in Q4 2025.
- 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.
Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.